ArticleScientific reports2026
Non-targeted metabolomics and postbiotics survey of an Iranian Koupa cheese Lactiplantibacillus plantarum isolate.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial postbiotics, bioactive compounds produced by probiotic bacteria, offer enhanced stability and safety compared with live microorganisms, making them valuable candidates for functional foods and therapeutic applications. In the present study, the probiotic properties and postbiotic compounds of a Lactiplantibacillus plantarum strain isolated from a traditional Iranian cheese were investigated. The strain exhibited a 71.28% survival rate under simulated gastrointestinal (SGI) conditions and demonstrated cell surface hydrophobicity and auto-aggregation capabilities of 60.39% and 54.30%, respectively. The cell-free supernatant (CFS) of bacterial culture was extracted with methanol and subsequently fractionated using n-hexane and ethyl acetate. A bioassay-guided fractionation approach was applied to the CFS, involving the identification of the most effective antibacterial extract/fraction against selected microorganisms, the isolation of potent antibacterial fractions via Sephadex LH-20 column, and identification of the active compounds through liquid chromatography-mass spectrometry. EtOAc proved to be the most effective solvent for extracting antibacterial compounds. Fractions 4 and 5 exhibited the highest inhibitory effect against Staphylococcus aureus and Escherichia coli, respectively. Identification of nocardamine and cyclic dipeptides, specifically diketopiperazines such as cyclo(Hyp-Leu) and cyclo(Tyrosyl-Prolyl), as major bioactive constituents in these fractions underscores their notable potential for enhancing health benefits and combating pathogenic bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.